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Objectives: to compare the patency of PTFE (Polytetrafluoroethylene) and unsealed knitted Dacron femoro-popliteal
bypasses.
Design: multi-centre prospective randomised trial.
Materials and methods: of 203 patients randomised, 194 were included in the final analysis (103 Dacron grafts and
91 PTFE grafts). The median follow-up was 36 months (range: 6–72 months); the distal anastomosis was above-knee in
141 and below-knee in 53 cases. Univariate comparisons of patency were made by the Kaplan–Meier method, multivariate
calculations on the effects of covariables by a Cox regression analysis.
Results: there was no difference regarding primary and secondary patency or limb salvage between Dacron and PTFE.
The primary 3-year patency for Dacron grafts was 64% (95% confidence interval [C.I.] 55–74%) and for PTFE grafts
61% (C.I. 49–72%). The corresponding 3-year secondary patency was 81% (C.I. 73–89%) and 75% (C.I. 65–86%)
respectively, the limb salvage rate 90% (C.I. 84–96%) and 91% (C.I. 84–97%). Upon multivariate analysis below-knee
anastomosis was the principal independent predictor of primary graft failure (risk ratio 1.7 [C.I. 1.05–2.8]), impaired
secondary patency was associated with infragenicular bypass (risk ratio 3.3 [C.I. 1.8–6.3]) and distal gangrene (risk ratio
[C.I. 1.01–3.8] p=0.048), major amputation was independently predicted by below-knee bypass, tissue necrosis, and poor
run-off index.
Conclusions: PTFE and Dacron are equally suitable for femoro-popliteal bypass.
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Introduction the surgeon considered a prosthetic graft to be the
most appropriate choice. The protocol was in ac-
There is broad consensus that autologous vein results cordance with the declaration of Helsinki and was
in superior long-term patency of infragenicular by- approved by the ethical committee of the University
pass.1,2 However, if autologous vein is not available, of Heidelberg. The following centres contributed to
PTFE (Polytetrafluoroethylene) has been the most pop- this study: Chirurgische Universita¨tsklinik Heidelberg,
ular choice.3–6 However, the preference for PTFE over Universita¨tsklinikum Mannheim, Josefskrankenhaus
Dacron is not evidence based.7,8 This trial was planned Heidelberg, Diakonissenkrankenhaus Karslruhe,
at a time when no conclusive evidence was available Allgemeines Krankenhaus Hamburg-Altona, Alfried-
to justify the preferential use of PTFE grafts.9 Kurpp-Krankenhaus Essen.
Materials and Methods
Inclusion criteria
Study design Indication for artificial graft of at least 20 cm length
with proximal anastomosis at the femoral artery. Both
The study included patients requiring a femoro-pop- artherosclerotic occlusions and popliteal aneurysms
liteal bypass either above-knee or below-knee where could be included. For above-knee bypass the choice
between autologous vein and prosthetic graft was left
∗ Please address all correspondence to: S. Post, Chirurgische Klinik, to the decision of the surgeon who could opt forKlinikum Mannheim der Universita¨t Heidelberg, 68135 Mannheim,
Germany. sparing the saphenous vein.
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Exclusion criteria type of anastomosis (end-to-end vs end-to-side) was
left to the choice of the surgeon. Only three of the
• Infections at operation sites; patients with below-knee bypass received a distal vein
• Emergency surgery for acute ischaemia; cuff.
• Distal anastomosis below the origin of the anterior
tibial artery; Concomitant therapy
• Composite grafts or jump grafts; Any type of pre- or intraoperative inflow re-
• No preoperative angiography available sufficient to construction or perioperative minor amputations for
judge distal run-off; gangrene were allowed but nevertheless recorded. All
• Previous inclusion in this study either for a contra- patients were treated with heparin perioperatively
lateral bypass or an earlier ipsilateral one (sim- (dosage and type of administration not standardised).
ultaneous bilateral grafts could be included just with Upon discharge the patients were required to receive
one side); either anti-platelet drugs, heparin or coumadin.
• Concomitant diseases expected to limit life ex-
pectancy to below 3 years at the time of ran- Primary end-point
domisation; Any occlusion of the graft occurring after the patient
• No informed consent to randomisation or un- left the operating theatre, i.e. primary patency was
likelihood of regular follow-up (e.g. due to serious chosen as the primary outcome measure. This was
doubts regarding compliance); used in the sense of unassisted primary patency,2
• Contraindications to all types of anticoagulants peri- i.e. in those cases where impeding graft occlusion
operatively (upon discharge the patients were re- necessitated reinterventions, the primary end-point
quired to receive either anti-platelet drugs, heparin was reached at this moment. In case of graft occlusion
or coumadin); later withdrawal of anticoagulants outside medical supervision the time point of marked
for any reasons was recorded but was not considered increase in pain or reduction in pain-free walking
violation of the protocol; distance was considered as time of graft occlusion. In
• Availability of suitable autologous vein (for infra- case of asymptomatic occlusion the half-time between
genicular bypass only). Criteria for suitability of the two follow-up visits was considered. Duplex scan
saphenous vein were not predetermined. and/or angiography were performed in any case of
clinical deterioration and/or clinical suspicion of graft
Randomisation occlusion.
Patients were randomised to either treatment arm
intraoperatively by sealed envelopes. The order of Secondary end-points
assignment had been generated by random digits from Secondary patency and limb salvage (avoiding major
a statistical software package (SAS). The envelopes amputation) were chosen as secondary outcome meas-
were drawn only following surgical exposure of the ures.
sites of proximal and distal anastomosis and judging
the vessels appropriate for the intended reconstruction. Sample size
Randomisation was stratified both for participating The study was designed to detect a difference between
hospital and for the site of distal anastomosis (supra- 50% and 70% primary patency after 3 years with =
genicular vs infragenicular). 0.05 and =0.2. The expectation of a 20% difference
came out of a retrospective analysis within the de-
Materials partmental records of the senior author demonstrating
Patients assigned to the “DACRON” group received an advantage of this magnitude in favour of Dacron
unsealed knitted polyester velour grafts (“Microvel” grafts. For actuarial analysis by two-sided log-rank
Meadox Company, Ratingen/Germany, taken over by test this would require 193 patients for analysis.10
Boston Scientific Vascular during the course of the Assuming a drop-out rate of 5% we planned to ran-
study); for infragenicular anastomosis spiral-enforced domise a total of 203 patients. A planned interim
protheses were applied. Dacron protheses were sealed analysis was performed after randomisation of 100
by autologous blood intraoperatively. Patients as- patients showing no conclusive evidence for early
signed to the “PTFE” group received “Thin wall TW” termination of the study according to preset criteria.
grafts above knee and “Ring removable RTW” grafts
infragenicular (W.L. Gore Associates, Putzbrunn/Ger- Follow-up
Patency of graft upon primary discharge had to bemany). Both type and size of suture materials as well
as the diameter of the prosthesis (6 or 8 mm) or the proven by either angiography or duplex sonography.
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Table 1. Group comparison for patient and disease characteristics.
Parameter DACRON PTFE
n 103 91
Age
median [range] 65 [40–84] yrs 68 [47–84] yrs
patients aged >65 52 (50%) 51 (56%)
Female (n) 27 (27%) 21 (24%)
Infragenicular bypass 27 (26%) 26 (29%)
Duration of operation
median [range] 130 [65–300] min 135 [70–290] min
cases with >=180 min 31 (30%) 23 (25%)
Simultaneous operations 33 (32%) 22 (24%)
Diameter of graft 8 mm∗ 11 (11%) 6 (7%)
Run-off Index24
4
100
Years
Dacron
%
0
Grafts at risk
Primary patency (overall)
1 2 3
16103 69 55 28Dacron
791 60 40 22PTFE
20
40
60
80
PTFE
median [range] 3.7 [1.0–7.5] 4.0 [1.0–10.0]
patients with 49 (46%) 51 (56%) Fig. 1. The graph shows the results of actuarial analysis for the
index>=4 primary endpoint, i.e. unassisted primary patency. Despite some
Diabetes mellitus more early graft occlusions with Dacron within the first months (11
non-insulin/insulin 17/12 12/8 vs 4 occlusions within 2 months) there was no significant difference
dep. between the treatment arms (p=0.89).
Smoker (never/ 34/30/39 28/24/39
previous/active)
Renal failure 13 (13%) 12 (13%)
ResultsDistal gangrene (Stage IV) 26 (25%) 17 (19%)
Critical limb ischaemia§ 36 (35%) 26 (29%)
Contributing centre# Recruitment of patients started in September 1993 andA 29 21
was terminated after randomisation of the plannedB 18 17
C 20 20 203 patients in October 1998. Due to primary dropout
D 16 14 of nine patients (violation of inclusion or exclusionE 16 16
criteria in three cases and refusal of patients to show
∗All other grafts were 6 mm in diameter. up for any follow-up visit in six cases) a total of 194
§ The remaining patients had intermittent claudication except two patients were included in the final analysis. At thecases in each group operated for popliteal aneurysms.
time of this analysis a median follow-up of 36 months# A sixth centre contributed the remaining seven cases.
(range: 6–72 months) was reached. A total of 141
patients received a supragenicular bypass, 53 an infra-
genicular bypass. Table 1 lists the distribution of im-
Planned follow-up visits were scheduled to take place portant covariables among the treatment arms.
after 3 and 6 months as well as 1, 2, 3, 4, and 5 years
postoperatively. Extraordinary visits were performed
in case of any clinical or subjective deterioration.
Primary patency
Figure 1 shows the data on overall unassisted primary
patency of the grafts. As it is easily visible there was
actually no difference between the two treatment armsStatistical analysis
(log-rank test p=0.89): the actuarial 3-year patency for
Dacron grafts was 64% (95% confidence interval [CI]Differences were considered significant at p<0.05 (two-
sided). Patency and limb salvage data were estimated 55–74%) and for PTFE grafts 61% (C.I. 49–72%). Uni-
variate analysis of the potentially important co-by the Kaplan–Meier method comparing both treat-
ment arms by log-rank test. Multivariate analysis was variables revealed a significant impact on primary
patency for infragenicular bypass (p=0.03, log-rankperformed by the Cox proportional-hazards model
with stepwise variable selection (p<0.05 for entry and test), poor run-off (p=0.046), and the presence of
critical limb ischaemia (p=0.02). In multivariate ana-removal of variables from the model). The covariables
listed in Table 1 were included in the multivariate lysis the only significant variable contributing to prim-
ary patency was the site of distal anastomosis whereanalysis provided a p-value below 0.25 was reached
on univariate analysis. The type of graft was always infragenicular bypass resulted in an increased risk
ratio of 1.7 (C.I. 1.05–2.8, p=0.03). Upon subgroupincluded in multivariate calculations. Calculations
were performed by the SAS statistical software pack- analysis for this parameter it was obvious that there
was a markedly worse outcome for infragenicularage (SAS Institute, Cary, NC, U.S.A.).
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success (26 Dacron grafts, 16 PTFE grafts). The in-
creased number of early occlusions in Dacron grafts
(Fig. 1) was no longer visible upon looking at sec-
ondary patency leading to almost identical secondary
patency rates for both types of graft. The actuarial 3-
year secondary patency for Dacron grafts was 81%
(C.I. 73–89%) and for PTFE grafts 75% (C.I. 65–86%).
Univariate analysis of the covariables showed a sig-
nificantly decreased secondary patency for infra-
genicular bypass (p=0.0001), distal gangrene (p=
0.005), as well as critical limb ischaemia (p=0.002). In
addition, bypasses performed in centre A had de-
0 3
100
Years
Dacron
%
Grafts at risk
Above knee bypass: Primary patency
1 2
2176 54 44Dacron
1365 41 27PTFE
20
40
60
80
PTFE
creased secondary patency (p=0.009) which was easily
Fig. 2. Calculations of actuarial primary patency for the subgroup explainable by the increased incidence of below-knee
with above-knee distal anastomosis. There was no significant dif- bypass in this centre. Accordingly, on multivariateference between the treatment arms (log-rank test p=0.35). Note
analysis infragenicular anastomosis (risk ratio 3.3 [C.I.that beyond 2.5 years postoperatively we did not observe any
occlusion in above-knee bypasses. 1.8–6.3] p=0.0002) and distal gangrene/Fontaine stage
IV disease (risk ratio 2.0 [C.I. 1.01–3.8] p=0.048) were
independently predictive of impaired secondary pat-
ency.
Amputation
Limb salvage was successfully achieved in most of the
cases. At 3 years postoperatively the rate was 90%
(C.I. 84–96%) in the DACRON arm and 91% (C.I.
84–97%) in the PTFE treatment arm (p=0.56). Uni-
variate analysis showed six variables to be associated
0 3
100
Years
Dacron%
Grafts at risk
Below knee bypass: Primary patency
1 2
727 15 11Dacron
926 19 13PTFE
20
40
60
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with impaired rates of limb salvage: infragenicular
Fig. 3. Calculations of actuarial primary patency demonstrates the
anastomosis (p=0.0001), distal gangrene (p=0.0001),worse outcome for below-knee bypass as compared with above-
knee in Figure 2. The difference between the treatment arms was critical limb ischaemia (p=0.0004), duration of primary
not significant (p=0.16). operation exceeding 3 h (p=0.003), poor run-off index
(p=0.007), and operation in centre A (p=0.04). Uponbypass. Differences in primary patency between Da-
multivariate analysis three of these remained in-cron and PTFE for different sites of distal anastomosis
dependently associated with major amputations:(Figs 2 and 3) were not statistically significant neither
below-knee bypass (risk ratio 4.2 [C.I. 1.8–10.1] p=on univariate nor on multivariate calculations. In
0.001), tissue necrosis/Fontaine stage IV disease (risksupragenicular bypasses the 3-year patency for Dacron
ratio 3.9 [C.I. 1.6–9.1] p=0.002), as well as a poorgrafts was 70% (C.I. 60–81%) and for PTFE grafts 62%
run-off index (risk ratio 3.4 [C.I. 1.1–10.1] p=0.03)(C.I. 50–75%) whereas in infragenicular bypasses the
decreased the chance of limb salvage.numbers were 46% (C.I. 26–66%) and 60% (C.I. 37–82%)
for Dacron and PTFE respectively. When the multi-
variate analysis was repeated with stratification for
the site of distal anastomosis, poor run-off (index of
Discussion4 or above) was predictive of worse outcome (risk
ratio 1.7, C.I. 1.02–2.7, p=0.04). Due to the shortcomings of retrospective data11 the
present results will be compared only with previous
randomised trial data. An early prospective study
which was partly randomised compared 36 PTFE withSecondary patency
10 composite Dacron-vein below-knee bypasses; the
authors reached the conclusion that further use ofIn 67 grafts a primary occlusive event was observed. Of
these 42 could be recanalised – at least with temporary Dacron-vein composites was not justified.12 A German
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trial randomised 250 patients with supragenicular by- patients19 there may be a remarkable workload to
achieve long-term patency.20pass. Unfortunately, since a preliminary report on the
Since the widespread acceptance of PTFE as graftfirst 103 patients no further data of this trial have been
material for infrainguinal bypass surgery it took morepublished. Up to 18 months of follow-up no significant
than two decades to prove that it may be no better thandifference between PTFE and Dacron grafts had been
the old-fashioned Dacron. We do hope that ongoing ordetectable.13
future developments of innovative prostheticA North American multicentre trial14 has been re-
materials21,22 or modifications in surgical technique23ported recently with a prolonged follow-up.15 In 240
will reach the same level of evidence within shorterabove-knee grafts no difference in patency could be
time.detected between PTFE and Dacron grafts. Lastly, a
randomised trial from Australia with a total of 108
patients (75 above-knee and 33 below-knee grafts)
confirmed that there is no difference in primary and
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